ACV Auctions (ACVA) Form 144 Notice: Option Exercise and Proposed Sale

Rhea-AI Filing Summary

Form 144 notice for ACV Auctions Inc. (ACVA) reports that 1,750 shares of Common stock were acquired and are proposed to be sold following an exercise of stock options on 09/15/2025. The filing shows the securities were acquired from the issuer, paid in cash, and the proposed sale is through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $17,517.50. The issuer's outstanding shares are listed as 172,107,121. The filer indicates no securities sold in the past three months and includes the standard representation about no undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine director/insider option exercise and proposed sale of 1,750 shares; immaterial relative to outstanding float.

The filing documents a typical post-exercise disposition of shares: 1,750 common shares acquired via option exercise on 09/15/2025 with cash payment and a proposed sale through Morgan Stanley Smith Barney. The aggregate value reported is $17,517.50 against 172,107,121 outstanding shares, indicating the transaction size is negligible relative to the company's total shares outstanding and unlikely to move market valuation.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure consistent with Rule 144; includes standard representation about material non-public information.

This Form 144 supplies required details for a Rule 144 sale: acquisition date, nature (option exercise), payment method, broker, and proposed sale date. The notice also affirms the signer does not possess undisclosed material adverse information and records no sales in the prior three months. From a governance perspective, the filing appears procedural and compliant with disclosure obligations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1750	17517.50	172107121	09/15/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/15/2025	Exercise of Stock Options	Issuer			1750	09/15/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did ACVA report in this Form 144?

The filer reported a proposed sale of 1,750 common shares acquired by exercise of stock options on 09/15/2025, to be sold via Morgan Stanley Smith Barney on the NYSE with aggregate value $17,517.50.

Was payment made in cash for the ACVA shares?

Yes. The Date of Payment is listed as 09/15/2025 and the Nature of Payment is Cash.

Does the filing show any ACVA securities sold in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

How material is the proposed sale relative to ACVA's outstanding shares?

The proposed sale of 1,750 shares versus 172,107,121 outstanding shares is insignificant in size based on the figures reported in this filing.

Which broker is handling the proposed sale for ACVA?

The broker named is Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY.